Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors

Grant

Date/time Interval

  • May 21, 2019 - May 20, 2024
  • Total Award Amount

  • 118300.00
  • Direct Costs

  • 91000.00
  • Sponsor Award Id

  • Contributor

  • Elizabeth Alva   Investigator  
  • Emily Johnston   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Jamie Aye   Investigator  
  • Kimberly Whelan M.D.   Investigator  
  • Laura Metrock   Investigator